DeepCure

About

Headcount over time

Offices

Q&A

What is DeepCure's primary focus?

DeepCure is an AI-driven drug discovery company that develops novel small molecule therapeutics for immune and inflammatory diseases.

What is DeepCure's total funding to date?

DeepCure has raised a total of $71.4 million USD.

When did DeepCure close its most recent funding round and who led it?

In April 2024, DeepCure closed an A Round of $24.6 million USD, led by IAG Capital Partners.

Who are the co-founders of DeepCure?

The co-founders of DeepCure are Kfir Schreiber (CEO), Joseph Jacobson, and Thrasyvoulos Karydis (CTO).

What is the core technology behind DeepCure's drug discovery platform?

DeepCure utilizes a chemistry platform that integrates AI, physics-based tools, and automated chemical synthesis to identify novel molecules, leveraging deep learning algorithms, cloud computing, and a proprietary chemistry database.

What was a significant collaboration announced by DeepCure in January 2023?

In January 2023, DeepCure collaborated with Biosero to establish a fully automated, AI-powered chemistry synthesis platform.

Team · 22

Kfir Schreiber

Founder · CEO & Co-Founder

Joseph Jacobson

Founder · Co-Founder

Thrasyvoulos Karydis

Founder · CTO & Co-Founder

Han Lim

Chief Business Officer

Luca Rastelli

Chief Scientific Officer

Georg Duenstl

VP of Drug Discovery

Derek Miller

VP, Head of Platform Research

Steven Ferrara

Director of Medicinal Chemistry

Ayelet Wagner Azran

Head of People Operations

Chris MacNaughton

Software Architect

George Bikos

Data Engineer

Mark Schroering

Associate Director Of Engineering, Lead Software Architect

Matthew Tieman

Staff Machine Learning Engineer

Yarden Ziv

Senior Automation Engineer

Ofir Bar

Analytical & Purification scientist

Jason Dinges

Director

Ehsan Jabbarzadeh

Director

Shahar Tzafrir

Director

Alex Kash

Observer

Yonatan Mandelbaum

Observer

Orly Dorot

Senior Scientist

Gerald Chan

Board Member

Sectors & technology

Tags